PMC3608194

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Candesartan produced the greatest improvement in executive function, with TMT Part B improving by 17.1 seconds versus 4.2 seconds for HCTZ and worsening by 14.4 seconds for lisinopril, with significan

Effect: improvement; TMT-B improved by 17.1 seconds

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines

Despite significant decreases in sitting blood pressure (21-28 mmHg systolic reduction), antihypertensive therapy was not associated with increased orthostatic blood pressure declines or worsening of

Effect: null; No increases in orthostatic BP declines in any group; no worsening of orthostatic BFV declines